Search

Your search keyword '"Vivo S"' showing total 98 results
Start Over Author "Vivo S"
98 results on '"Vivo S"'

2. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY

Author

Viola, A., primary, Ventimiglia, M., additional, Sparacino, A., additional, D'Antonio, E., additional, Orlando, A., additional, De Vivo, S., additional, Pugliese, D., additional, Varca, S., additional, Scaldaferri, F., additional, Ribaldone, D.G., additional, Armandi, A., additional, Balestrieri, P., additional, Castiglione, F., additional, Savarino, E.V., additional, Cappello, M., additional, Viganò, C., additional, Mocci, G., additional, Allocca, M., additional, Principi, M.B., additional, Soriano, A., additional, Onali, S., additional, Bodini, G., additional, Riguccio, G., additional, Festa, S., additional, Bertani, L., additional, Checchin, D., additional, Caprioli, F., additional, and Fries, W., additional

Published
2024
Full Text
View/download PDF

3. Clinical and Neurocognitive Predictors of Functional Outcome in Depressed Patients with Partial Response to Treatment: One Year Follow-Up Study

Author

Castellano S, Torrent C, Petralia MC, Godos J, Cantarella RA, Ventimiglia A, De Vivo S, Platania S, Guarnera M, Pirrone C, Drago F, Vieta E, Di Nuovo S, Popovic D, and Caraci F

Subjects
major depression, ssri, snri, cognition, psychometric tools, antidepressant drugs, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Sabrina Castellano,1 Carla Torrent,2 Maria Cristina Petralia,3 Justyna Godos,4 Rita Anna Cantarella,5 Andrea Ventimiglia,6 Simona De Vivo,6 Silvia Platania,1 Maria Guarnera,7 Concetta Pirrone,1 Filippo Drago,4 Eduard Vieta,2 Santo Di Nuovo,1 Dina Popovic,2,8,* Filippo Caraci4,9,* 1Department of Educational Sciences, University of Catania, Catania, Italy; 2Barcelona Bipolar Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; 3IRCCS Centro Neurolesi Bonino Pulejo, Messina, Italy; 4Oasi Research Institute-IRCCS, Troina 94018, Italy; 5Department of Mental Health, ASP3 Catania, Catania, Italy; 6Villa dei Gerani Clinic ASP3 Catania, Catania, Italy; 7Faculty of Human and Social Sciences, University of Enna “KORE”, Enna, Italy; 8Bipolar Disorders Program, Sheba Medical Center, Ramat Gan, Israel; 9Department of Drug Sciences, University of Catania, Catania, Italy*These authors contributed equally to this workCorrespondence: Sabrina CastellanoDepartment of Educational Sciences, University of Catania, Via Ofelia 1, Catania 95124, ItalyTel +39 0952508060Fax +39 0952508070Email sabrina.castellano@unict.itBackground: Cognitive dysfunction represents a distinct biological and clinical dimension in major depression disorders (MDD) and cognitive performance strongly affects psychosocial functioning in patients diagnosed with MDD.Objective: To assess which neurocognitive variables at baseline predict the functional outcome of MDD patients in a 1-year follow-up study as assessed by Functioning Assessment Short Test (FAST) and whether the improvement observed on affective and cognitive symptoms in our 12 week-prospective observational study after treatment with selective serotonin reuptake inhibitors (SSRIs) and selective noradrenalin reuptake inhibitors (SNRIs) can affect the following long-term psychosocial functional outcome at 1 year in the same MDD patients.Methods: We recruited a total of 31 patients (8 males; 23 females) with MDD who had previously completed a pharmacological treatment with SSRIs (n = 22) or SNRIs (n = 9) for 12 weeks, and then continued the same pharmacological treatment for 1 year. After an average 1-year follow-up, they were interviewed with the FAST to assess functional outcome. Multivariate analyses were applied to identify clinical and neurocognitive predictors of functional outcome.Results: Total Montreal Cognitive Assessment (MoCA), Digit Span forward (Span F) and backward (Span B), and 15 Rey words immediate recall (Rey I) scores significantly correlated with FAST. However, after performing regression models only Rey immediate recall score was useful to predict long-term functional outcome (Pearson correlation coefficient R= − 0.68, p

Published
2020

4. Intermuscular technique for implantation of the subcutaneous implantable defibrillator: a propensity-matched case-control study

Author

Botto, G, Ziacchi, M, Nigro, G, D'Onofrio, A, Dello Russo, A, Francia, P, Viani, S, Pisano, E, Bisignani, G, Caravati, F, Migliore, F, De Filippo, P, Ottaviano, L, Rordorf, R, Manzo, M, Canevese, F, Lovecchio, M, Valsecchi, S, Checchi, L, Casale, M, Schintu, B, Scalone, A, Tola, G, Setzu, A, Curcio, A, Santoro, A, Baiocchi, C, Gentilini, R, Lunghetti, S, Solimene, F, Shopova, G, Schillaci, V, Arestia, A, Agresta, A, Bianchi, S, Rossi, P, Cauti, F, La Greca, C, Pecora, D, Ammirati, F, Santini, L, Mahfouz, K, Colaiaco, C, Vicentini, A, Savastano, S, Petracci, B, Sanzo, A, Baldi, E, Casula, M, Perego, G, Rella, V, Bianchi, V, Tavoletta, V, De Vivo, S, Palmisano, P, Accogli, M, Milanese, G, Pepi, P, Nicolis, D, Mariani, M, Pagani, M, Bonfantino, M, Caccavo, V, Grimaldi, M, Katsouras, G, Forleo, G, Chieffo, E, Tavarelli, E, Brambilla, R, Pani, A, Giammaria, M, Lucciola, M, Amellone, C, Uran, C, Baroni, M, Ferrari, P, Leidi, C, Drago, F, Silvetti, M, Pazzano, V, Russo, S, Remoli, R, Battipaglia, I, Cazzoli, I, Saputo, F, Devecchi, C, Barbonaglia, L, Viscusi, M, Brignoli, M, Mattera, A, Pedretti, S, Lupi, A, Tommasi, S, Kol, A, Gatto, M, Persi, A, Gonella, A, Rossetti, G, Menardi, E, Rossini, R, Notarstefano, P, Nesti, M, Fraticelli, A, Carreras, G, Donzelli, S, Marini, C, Tordini, A, Lazzari, L, Sartori, P, Di Donna, P, Mascia, G, Capogrosso, P, Magliano, P, Colimodio, M, Sala, S, Mazzone, P, Della Bella, P, Coppolino, A, Arena, G, Borrello, V, Ratti, M, Bartoli, C, Palano, F, Adduci, C, Torriglia, A, Laffi, M, Esposito, C, Giano, A, Franculli, F, Pangallo, A, De Bonis, S, Sarubbi, B, Colonna, D, Correra, A, Romeo, E, Rapacciuolo, A, Liguori, V, Viggiano, A, Strisciullo, T, Biffi, M, Diemberger, I, Martignani, C, Piro, A, Lavalle, C, Magnocavallo, M, Ricciardi, D, Calabrese, V, Gioia, F, Picarelli, F, Licciardello, G, Busacca, G, Calvi, V, Lamberti, F, Lumia, G, Bellini, C, Bianchi, C, Savarese, G, Andreoli, C, Pimpinicchio, L, Pellegrini, D, Giorgi, D, Bovenzi, Busoni, F, Daleffe, E, Facchin, D, Rebellato, L, Stifano, G, Magliano, G, Sergi, D, Barone, L, Morgagni, R, Casella, M, Guerra, F, Cipolletta, L, Molini, S, De Lucia, R, Di Cori, A, Grifoni, G, Paperini, L, Segreti, L, Soldati, E, Zucchelli, G, Russo, V, Rago, A, Ammendola, E, Papa, A, Pieragnoli, P, Ricciardi, G, Perrotta, L, Botto G. L., Ziacchi M., Nigro G., D'Onofrio A., Dello Russo A., Francia P., Viani S., Pisano E., Bisignani G., Caravati F., Migliore F., De Filippo P., Ottaviano L., Rordorf R., Manzo M., Canevese F. L., Lovecchio M., Valsecchi S., Checchi L., Casale M. C., Schintu B., Scalone A., Tola G., Setzu A., Curcio A., Santoro A., Baiocchi C., Gentilini R., Lunghetti S., Solimene F., Shopova G., Schillaci V., Arestia A., Agresta A., Bianchi S., Rossi P., Cauti F. M., La Greca C., Pecora D., Ammirati F., Santini L., Mahfouz K., Colaiaco C., Vicentini A., Savastano S., Petracci B., Sanzo A., Baldi E., Casula M., Perego G. B., Rella V., Bianchi V., Tavoletta V., De Vivo S., Palmisano P., Accogli M., Milanese G., Pepi P., Nicolis D., Mariani M., Pagani M., Bonfantino M. V., Caccavo V., Grimaldi M., Katsouras G., Forleo G. B., Chieffo E., Tavarelli E., Brambilla R., Pani A., Giammaria M., Lucciola M. T., Amellone C., Uran C., Baroni M., Ferrari P., Leidi C., Drago F., Silvetti M. S., Pazzano V., Russo S., Remoli R., Battipaglia I., Cazzoli I., Saputo F., Devecchi C., Barbonaglia L., Viscusi M., Brignoli M., Mattera A., Pedretti S., Lupi A., Tommasi S., Kol A., Gatto M. C., Persi A., Gonella A., Rossetti G., Menardi E., Rossini R., Notarstefano P., Nesti M., Fraticelli A., Carreras G., Donzelli S., Marini C., Tordini A., Lazzari L., Sartori P., Di Donna P., Mascia G., Capogrosso P., Magliano P., Colimodio M., Sala S., Mazzone P., Della Bella P., Coppolino A., Arena G., Borrello V., Ratti M., Bartoli C., Palano F., Adduci C., Torriglia A., Laffi M., Esposito C., Giano A., Franculli F., Pangallo A., De Bonis S., Sarubbi B., Colonna D., Correra A., Romeo E., Rapacciuolo A., Liguori V., Viggiano A., Strisciullo T., Biffi M., Diemberger I., Martignani C., Piro A., Lavalle C., Magnocavallo M., Mariani M. V., Ricciardi D., Calabrese V., Gioia F., Picarelli F., Licciardello G., Busacca G., Calvi V. I., Lamberti F., Lumia G., Bellini C., Bianchi C., Savarese G., Andreoli C., Pimpinicchio L., Pellegrini D., Giorgi D., Busoni F., Daleffe E., Facchin D., Rebellato L., Stifano G., Magliano G., Sergi D., Barone L., Morgagni R., Casella M., Guerra F., Cipolletta L., Molini S., De Lucia R., Di Cori A., Grifoni G., Paperini L., Segreti L., Soldati E., Zucchelli G., Russo V., Rago A., Ammendola E., Papa A., Pieragnoli P., Ricciardi G., Perrotta L., Botto, G, Ziacchi, M, Nigro, G, D'Onofrio, A, Dello Russo, A, Francia, P, Viani, S, Pisano, E, Bisignani, G, Caravati, F, Migliore, F, De Filippo, P, Ottaviano, L, Rordorf, R, Manzo, M, Canevese, F, Lovecchio, M, Valsecchi, S, Checchi, L, Casale, M, Schintu, B, Scalone, A, Tola, G, Setzu, A, Curcio, A, Santoro, A, Baiocchi, C, Gentilini, R, Lunghetti, S, Solimene, F, Shopova, G, Schillaci, V, Arestia, A, Agresta, A, Bianchi, S, Rossi, P, Cauti, F, La Greca, C, Pecora, D, Ammirati, F, Santini, L, Mahfouz, K, Colaiaco, C, Vicentini, A, Savastano, S, Petracci, B, Sanzo, A, Baldi, E, Casula, M, Perego, G, Rella, V, Bianchi, V, Tavoletta, V, De Vivo, S, Palmisano, P, Accogli, M, Milanese, G, Pepi, P, Nicolis, D, Mariani, M, Pagani, M, Bonfantino, M, Caccavo, V, Grimaldi, M, Katsouras, G, Forleo, G, Chieffo, E, Tavarelli, E, Brambilla, R, Pani, A, Giammaria, M, Lucciola, M, Amellone, C, Uran, C, Baroni, M, Ferrari, P, Leidi, C, Drago, F, Silvetti, M, Pazzano, V, Russo, S, Remoli, R, Battipaglia, I, Cazzoli, I, Saputo, F, Devecchi, C, Barbonaglia, L, Viscusi, M, Brignoli, M, Mattera, A, Pedretti, S, Lupi, A, Tommasi, S, Kol, A, Gatto, M, Persi, A, Gonella, A, Rossetti, G, Menardi, E, Rossini, R, Notarstefano, P, Nesti, M, Fraticelli, A, Carreras, G, Donzelli, S, Marini, C, Tordini, A, Lazzari, L, Sartori, P, Di Donna, P, Mascia, G, Capogrosso, P, Magliano, P, Colimodio, M, Sala, S, Mazzone, P, Della Bella, P, Coppolino, A, Arena, G, Borrello, V, Ratti, M, Bartoli, C, Palano, F, Adduci, C, Torriglia, A, Laffi, M, Esposito, C, Giano, A, Franculli, F, Pangallo, A, De Bonis, S, Sarubbi, B, Colonna, D, Correra, A, Romeo, E, Rapacciuolo, A, Liguori, V, Viggiano, A, Strisciullo, T, Biffi, M, Diemberger, I, Martignani, C, Piro, A, Lavalle, C, Magnocavallo, M, Ricciardi, D, Calabrese, V, Gioia, F, Picarelli, F, Licciardello, G, Busacca, G, Calvi, V, Lamberti, F, Lumia, G, Bellini, C, Bianchi, C, Savarese, G, Andreoli, C, Pimpinicchio, L, Pellegrini, D, Giorgi, D, Bovenzi, Busoni, F, Daleffe, E, Facchin, D, Rebellato, L, Stifano, G, Magliano, G, Sergi, D, Barone, L, Morgagni, R, Casella, M, Guerra, F, Cipolletta, L, Molini, S, De Lucia, R, Di Cori, A, Grifoni, G, Paperini, L, Segreti, L, Soldati, E, Zucchelli, G, Russo, V, Rago, A, Ammendola, E, Papa, A, Pieragnoli, P, Ricciardi, G, Perrotta, L, Botto G. L., Ziacchi M., Nigro G., D'Onofrio A., Dello Russo A., Francia P., Viani S., Pisano E., Bisignani G., Caravati F., Migliore F., De Filippo P., Ottaviano L., Rordorf R., Manzo M., Canevese F. L., Lovecchio M., Valsecchi S., Checchi L., Casale M. C., Schintu B., Scalone A., Tola G., Setzu A., Curcio A., Santoro A., Baiocchi C., Gentilini R., Lunghetti S., Solimene F., Shopova G., Schillaci V., Arestia A., Agresta A., Bianchi S., Rossi P., Cauti F. M., La Greca C., Pecora D., Ammirati F., Santini L., Mahfouz K., Colaiaco C., Vicentini A., Savastano S., Petracci B., Sanzo A., Baldi E., Casula M., Perego G. B., Rella V., Bianchi V., Tavoletta V., De Vivo S., Palmisano P., Accogli M., Milanese G., Pepi P., Nicolis D., Mariani M., Pagani M., Bonfantino M. V., Caccavo V., Grimaldi M., Katsouras G., Forleo G. B., Chieffo E., Tavarelli E., Brambilla R., Pani A., Giammaria M., Lucciola M. T., Amellone C., Uran C., Baroni M., Ferrari P., Leidi C., Drago F., Silvetti M. S., Pazzano V., Russo S., Remoli R., Battipaglia I., Cazzoli I., Saputo F., Devecchi C., Barbonaglia L., Viscusi M., Brignoli M., Mattera A., Pedretti S., Lupi A., Tommasi S., Kol A., Gatto M. C., Persi A., Gonella A., Rossetti G., Menardi E., Rossini R., Notarstefano P., Nesti M., Fraticelli A., Carreras G., Donzelli S., Marini C., Tordini A., Lazzari L., Sartori P., Di Donna P., Mascia G., Capogrosso P., Magliano P., Colimodio M., Sala S., Mazzone P., Della Bella P., Coppolino A., Arena G., Borrello V., Ratti M., Bartoli C., Palano F., Adduci C., Torriglia A., Laffi M., Esposito C., Giano A., Franculli F., Pangallo A., De Bonis S., Sarubbi B., Colonna D., Correra A., Romeo E., Rapacciuolo A., Liguori V., Viggiano A., Strisciullo T., Biffi M., Diemberger I., Martignani C., Piro A., Lavalle C., Magnocavallo M., Mariani M. V., Ricciardi D., Calabrese V., Gioia F., Picarelli F., Licciardello G., Busacca G., Calvi V. I., Lamberti F., Lumia G., Bellini C., Bianchi C., Savarese G., Andreoli C., Pimpinicchio L., Pellegrini D., Giorgi D., Busoni F., Daleffe E., Facchin D., Rebellato L., Stifano G., Magliano G., Sergi D., Barone L., Morgagni R., Casella M., Guerra F., Cipolletta L., Molini S., De Lucia R., Di Cori A., Grifoni G., Paperini L., Segreti L., Soldati E., Zucchelli G., Russo V., Rago A., Ammendola E., Papa A., Pieragnoli P., Ricciardi G., and Perrotta L.

Abstract

Aims A previous randomized study demonstrated that the subcutaneous implantable cardioverter defibrillator (S-ICD) was noninferior to transvenous ICD with respect to device-related complications and inappropriate shocks. However, that was performed prior to the widespread adoption of pulse generator implantation in the intermuscular (IM) space instead of the traditional subcutaneous (SC) pocket. The aim of this analysis was to compare survival from device-related complications and inappropriate shocks between patients who underwent S-ICD implantation with the generator positioned in an IM position in comparison with an SC pocket. Methods and results We analysed 1577 consecutive patients who had undergone S-ICD implantation from 2013 to 2021 and were followed up until December 2021. Subcutaneous patients (n = 290) were propensity matched with patients of the IM group (n = 290), and their outcomes were compared. : During a median follow-up of 28 months, device-related complications were reported in 28 (4.8%) patients and inappropriate shocks were reported in 37 (6.4%) patients. The risk of complication was lower in the matched IM group than in the SC group [hazard ratio 0.41, 95% confidence interval (CI) 0.17-0.99, P = 0.041], as well as the composite of complications and inappropriate shocks (hazard ratio 0.50, 95% CI 0.30-0.86, P = 0.013). The risk of appropriate shocks was similar between groups (hazard ratio 0.90, 95% CI 0.50-1.61, P = 0.721). There was no significant interaction between generator positioning and variables such as gender, age, body mass index, and ejection fraction. Conclusion Our data showed the superiority of the IM S-ICD generator positioning in reducing device-related complications and inappropriate shocks.

Published
2023

5. Analysis of a Reaction-Diffusion Epidemic Model

Author

Cantó, B., Coll, C., Romero-Vivó, S., Sánchez, E., Allgöwer, Frank, Series editor, Morari, Manfred, Series editor, Cacace, Filippo, editor, Farina, Lorenzo, editor, Setola, Roberto, editor, and Germani, Alfredo, editor

Published
2017
Full Text
View/download PDF

6. C53 EFFECTS OF CARDIAC CONTRACTILITY MODULATION THERAPY ON LEFT VENTRICLE GLOBAL LONGITUDINAL STRAIN AND MYOCARDIAL MECHANO–ENERGETIC EFFICIENCY IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION

Author

Martucci, M, primary, Kittleson, M, additional, De Vivo, S, additional, D’Onofrio, A, additional, Ammendola, E, additional, Nigro, G, additional, Contaldi, C, additional, Errigo, V, additional, Pacileo, G, additional, and Masarone, D, additional

Published
2023
Full Text
View/download PDF

8. T.06.2 USTEKINUMAB IS A PROMISING OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE

Author

Macaluso, F.S., primary, Grova, M., additional, Mocciaro, F., additional, Di Mitri, R., additional, Privitera, A., additional, Distefano, M., additional, Vitello, A., additional, Camilleri, S., additional, Ferracane, C., additional, Pluchino, D., additional, Belluardo, N., additional, Giangreco, E., additional, Fries, W., additional, Viola, A., additional, Cappello, M., additional, D'Amato, L., additional, Bertolami, C., additional, Ventimiglia, M., additional, Renna, S., additional, Casa, A., additional, De Vivo, S., additional, and Orlando, A., additional

Published
2023
Full Text
View/download PDF

18. Six-Year Follow-Up of Intensive, Simulator-Based Pilot Training

Author

Lubner, M. (author), Dattel, A.R. (author), Allen, E. (author), Henneberry, D. (author), De Vivo, S. (author), Lubner, M. (author), Dattel, A.R. (author), Allen, E. (author), Henneberry, D. (author), and De Vivo, S. (author)

Abstract

In 2012, Vaughn College of Aeronautics and Technology initiated an intensive, simulator based, flight training program. Three cohorts, totaling 16 students, completed flight training with fewer flight hours than the United States average (ISAP, 2013). The students earned Federal Aviation Administration (FAA) Private Pilot certificates within 5 weeks, Instrument ratings in 3-4 weeks, Commercial certificates in an average of 20 weeks and Certificated Flight Instructor ratings in an average of 40 weeks. All participants met selection criteria, including completing their FAA Class III medical certificates, FAA Private Pilot Knowledge exams, a demonstration flight, financial counseling, having a grade point average of at least 3.0, and agreeing to remain substance-free during training. These 16 students and a comparison group of students who enrolled in traditional flight training at the college at that time have been followed over the past 6 years to observe factors associated with their career progression. Surveys were conducted by e-mail, phone, or in person to ask about flight training, career progression, and experiences of camaraderie, mentorship, and general satisfaction with their programs. This follow-up study found that 13 of the 16 students (81%) achieved their career goals of flying professionally. The comparison group has taken longer to complete flight training and proportionally fewer are flying professionally. Indicators of success in achieving professional pilot careers and networks included the cognitive variables related to intensive simulator-based training, camaraderie, shared learning experiences and opportunities to reflect on training.

Published
2019

19. Remote monitoring of atrial high rate episodes in pacemaker patients. the rapid study design

Author

Russo, V., Rago, A., Tavoletta, V., Bianchi, V., Carella, C., Ammirati, G., Viggiano, A., Vivo, S., Antonio RAPACCIUOLO, Nigro, G., D Onofrio, A., Russo, Vincenzo, Rago, Anna, Tavoletta, Vincenzo, Bianchi, Valter, Carella, Cristina, Ammirati, Giuseppe, Viggiano, Aniello, De Vivo, Stefano, Rapacciuolo, Antonio, Nigro, Gerardo, and D'Onofrio, Antonio

Subjects
Pacemaker, Atrial high rate episode, Remote monitoring, Atrial High Rate Episode, Cardiology and Cardiovascular Medicine, Atrial fibrillation, Original Research
Abstract

BACKGROUND: Remote Monitoring (RM) has been introduced for several years and nowadays most pacemakers are equipped with such a technology. RM can provide early detection of high atrial rate episodes (AHREs) onset and enable prompt medical intervention. However, there are still little data on the clinical reactions triggered by the AHRE detected by RM of pacemaker recipients and on their possible benefit on patients' outcome. METHODS/DESIGN: The RAPID study is a multicenter, prospective, non-interventional study designed to compare the time from onset to first physician's evaluation of AHRE episode with arrhythmic burden ≥5% (72 minutes) for pacemaker recipients without atrial fibrillation history, between patients followed with RM or conventionally with annual in-hospital visits. A total of 98 patients with implanted dual-chamber pacemaker, assigned to RM-OFF or RM-ON according to ordinary clinical site practice, will be followed for a total of 18 months. After the implant, patients will perform their first in-hospital follow-up visit at 1 month and then, in the RM-OFF group, patients will perform an in-hospital FU every 6 months, while in the active group, patients will be continuously monitored via RM until study termination. All AHREs and consequent medical interventions will be collected over the entire study period. DISCUSSION: The ongoing RAPID study will provide additional information on the role of RM in the management of AHRE detected in pacemaker patients without documented atrial fibrillation history in ordinary clinical practice

Published
2018

21. Efficacy and safety of dabigatran in a 'real-life' population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry

Author

Russo V, Bianchi V, Cavallaro C, Vecchione F, De Vivo S, Santangelo L, Sarubbi B, paolo calabrò, Nigro G, D'Onofrio A, Russo, V, Bianchi, V, Cavallaro, C, Vecchione, F, De Vivo, S, Santangelo, Lucio, Sarubbi, B, Calabro', Paolo, Nigro, Gerardo, and D'Onofrio, A.

Subjects
Male, Hemorrhage, Middle Aged, Antithrombins, Dabigatran, Cohort Studies, Stroke, Treatment Outcome, Italy, Risk Factors, Population Surveillance, Thromboembolism, Atrial Fibrillation, Prevalence, cardiovascular system, Humans, Female, Prospective Studies, Registries, cardiovascular diseases, Dyspepsia, Aged, Follow-Up Studies
Abstract

Dabigatran is a novel target specific oral anticoagulant for stroke prevention in non valvular atrial fibrillation. Little is still known about its real-world effectiveness and safety in the italian population. Aim of our study was to evaluate the efficacy and safety of dabigatran in a large single-center cohort of "real-life" italian population with non-valvular AF and to compare the results with those obtained from the RE-LY trial and the Medicare study.We studied a prospective cohort of 2108 patients (1119 male; mean age 69.4 ± 9.4 years) who started the oral anticoagulant treatment with dabigatran 110 mg twice-daily (DAB 110; N = 1075; 51%) or 150 mg twice-daily (DAB 150; N = 1033; 49%). Follow-up data were obtained trough outpatients visits each 3-6 months for assessing the clinical status, adherence to treatment, occurrence of side effects and major cardiovascular complications.In DAB 150 group the mean age was 64.9 ± 8.8 years, 56.8% of patients was male. CHA2DS2Vasc Score was ≥ 3 in 94.3% and HAS-BLED was ≥ 3 in 59.7%. In DAB 110 group (N = 1075) the mean age was 73.9 ± 7.5 years; 49.5% of patients was male. CHA2DS2Vasc Score was ≥ 3 in 73.4% and HAS-BLED was ≥ 3 in 87.4% of DAB 110 patients. One patient taking Dabigatran 110 mg bid had ischemic stroke without significantly neurological sequelae. In both groups, no patient experienced hemorrhagic stroke during the follow-up period. 147 patients (6.9%) of MonaldiCare population reported adverse effects from treatment with dabigatran, of whom 121 patients (5.7%) discontinued therapy. We reported one case of subarachnoid hemorrhage (0.05%) in a patient with high thrombo-embolic and high hemorrhagic risk score who was taking dabigatran 150 mg bid and one case (0.05%) of bladder bleeding in a patient who was taking dabigatran 110 mg bid. No major gastrointestinal bleeding was observed in the MonaldiCare population.MonaldiCare registry showed a safety profile of both dosages of dabigatran regarding major of fatal bleeding in a "real life" single center italian population at high thromboembolic and hemorrhagic risk. The majority of MonaldiCare patients tolerated dabigatran treatment without significant side effects. The efficacy of dabigatran was demonstrated by very low prevalence of ictus/TIA, also when patients underwent electrical AF cardioversion independently of the transesophageal examination.

Published
2015

24. [The stapler in total laryngectomy with closed technique]

Author

MANOLA M, LONGO F, DE VIVO S, VILLANO S, DE MARIA G, IONNA F., D'ANGELO, Luigi, Manola, M, D'Angelo, Luigi, Longo, F, DE VIVO, S, Villano, S, DE MARIA, G, and Ionna, F.

Subjects
Postoperative Complications, Fistula, Cutaneous Fistula, Surgical Stapling, Humans, Laryngectomy, Radiotherapy, Adjuvant, Pharyngeal Diseases, Combined Modality Therapy, Laryngeal Neoplasms, Retrospective Studies
Abstract

AIMS AND BACKGROUNDS: The use of the stapler in total laryngectomy with closed technique is described by the authors. MATERIALS AND METHODS: From October 1999 to December 2002, 27 total laryngectomy were performed, 15 with a stapler and 5 cases had a primary tracheoesophageal puncture. RESULTS: Only one patient developed a pharyngocutaneous fistula, no other patients experienced post-operative complications. All cases in this study had negative surgical margins. CONCLUSION: The correct indication for the use of the stapler is a tumor that needs a total laryngectomy, but completely endolaryngeal. The technique allows to remove the nso-gastric tube at the end of the first week after the operation, to avoid soiling the surgical field, to reduce the time in theatre. This technique seems to be safe as the traditional suture.

Published
2003

25. [Popliteal aneurysms. Personal experience]

Author

Matarazzo A, Sassi O, Giordano A, Anna FLORIO, Polichetti R, De Vivo S, Matarazzo, A, Sassi, O, Giordano, A, Florio, Anna, Polichetti, R, and DE VIVO, S.

Subjects
Male, Aneurysm surgery, Leg blood supply, Ischemia, Humans, Female, Popliteal Artery, Aneurysm
Abstract

Background. The 70% of peripheral aneurysms are localized at the popliteal artery; approximately one third of patients are asymptomatic, but the occurrence of complications (acute ischemia, rupture) endangers the survival of the leg. The purpose of this paper is to demonstre the validity of elective surgery for popliteal aneurysms, also for asymptomatic lesions. Methods. Twenty-seven popliteal aneurysms were observed in 20 patients; only 7 of these were affected by a unilateral lesion, other 7 patients by a bilateral lesion and the remainder 6 patients by a polydistrict association; 3 patients refused the surgical therapy which was proposed. Prosthetic grafting with exclusion or resection of the aneurysm has been practiced in 16 cases; one time only a Dacron graft was employed, while the autologous saphenous vein was employed in 15 cases. A locoregional thrombolysis has been performed in 3 patients, in presence of an acute peripheral ischemia. In 5 cases a conservative approach has been chosen; these were asymptomatic aneurysms with a

Published
2002

26. Prosthetic infections

Author

MATARAZZO A, SASSI O, DE VIVO S, MAINELLI R., FLORIO, Anna, Matarazzo, A, Sassi, O, Florio, Anna, DE VIVO, S, and Mainelli, R.

Published
2002

28. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.

Author

RUSSO, V., BIANCHI, V., CAVALLARO, C., VECCHIONE, F., DE VIVO, S., SANTANGELO, L., SARUBBI, B., CALABRÒ, P., NIGRO, G., and D'ONOFRIO, A.

Abstract

OBJECTIVE: Dabigatran is a novel target specific oral anticoagulant for stroke prevention in non valvular atrial fibrillation. Little is still known about its real-world effectiveness and safety in the italian population. Aim of our study was to evaluate the efficacy and safety of dabigatran in a large single-center cohort of "real- life" italian population with non-valvular AF and to compare the results with those obtained from the RE-LY trial and the Medicare study. PATIENTS AND METHODS: We studied a prospective cohor t of 2108 patients (1119 male; mean age 69.4 ± 9.4 years) who started the oral anticoagulant treatment with dabigatran 110 mg twice-daily (DAB 110; N = 1075; 51%) or 150 mg twice-daily (DAB 150; N = 1033; 49%). Follow-up data were obtained trough outpatients visits each 3-6 months for assessing the clinical status, adherence to treatment, occurrence of side effects and major cardiovascular complications. RESULTS: In DAB 150 group the mean age was 64.9 ± 8.8 years, 56.8% of patients was male. CHA2DS2Vasc Score was ≥3 in 94.3% and HASBLED was ≥3 in 59.7%. In DAB 110 group (N = 1075) the mean age was 73.9 ± 7.5 years; 49.5% of patients was male. CHA2DS2Vasc Score was ≥ 3 in 73.4% and HAS-BLED was ≥3 in 87.4% of DAB 110 patients. One patient taking Dabigatran 110 mg bid had ischemic stroke without significantly neurological sequelae. In both groups, no patient experienced hemorrhagic stroke during the follow-up period. 147 patients (6.9%) of MonaldiCare population reported adverse effects from treatment with dabigatran, of whom 121 patients (5.7%) discontinued therapy. We reported one case of subarachnoid hemorrhage (0.05%) in a patient with high thrombo-embolic and high hemorrhagic risk score who was taking dabigatran 150 mg bid and one case (0.05%) of bladder bleeding in a patient who was taking dabigatran 110 mg bid. No major gastrointestinal bleeding was observed in the MonaldiCare population. CONCLUSIONS: MonaldiCare registry showed a safety profile of both dosages of dabigatran regarding major of fatal bleeding in a "real life" single center italian population at high thromboembolic and hemorrhagic risk. The majority of MonaldiCare patients tolerated dabigatran treatment without significant side effects. The efficacy of dabigatran was demonstrated by very low prevalence of ictus/TIA, also when patients underwent electrical AF cardioversion independently of the transesophageal examination. [ABSTRACT FROM AUTHOR]

Published
2015

34. Early evaluation of atrial high rate episodes using remote monitoring in pacemaker patients: Results from the RAPID study

Author

Vincenzo Russo, Antonio Rapacciuolo, Anna Rago, Vincenzo Tavoletta, Stefano De Vivo, Giuseppe Ammirati, Valerio Pergola, Giovanni Domenico Ciriello, Paola Napoli, Gerardo Nigro, Antonio D'Onofrio, Russo, V., Rapacciuolo, A., Rago, A., Tavoletta, V., De Vivo, S., Ammirati, G., Pergola, V., Ciriello, G. D., Napoli, P., Nigro, G., and D'Onofrio, A.

Subjects
atrial fibrillation, atrial tachyarrhythmia, Cardiology and Cardiovascular Medicine, pacemaker, remote monitoring, atrial high rate episode
Abstract

Aim: Remote monitoring (RM) of implantable cardiac devices has enabled continuous surveillance of atrial high rate episodes (AHREs) with well-recognized clinical benefits. We aimed to add evidence on the role of the RM as compared to conventional follow-up by investigating the interval from AHRE onset to physician’s evaluation and reaction time in actionable episodes. Methods and Results: A total of 97 dual-chamber pacemaker recipients were followed with RM (RM-ON group; N=64) or conventional in-office visits (RM-OFF group; N=33) for 18months. In-office visits were scheduled at 1, 6, 12, and 18months in the RM-OFF group and at 1 and 18months in the RM-ON group. The overall AHRE rate was 1.98 per patient-year (95% confidence interval [CI], 1.76–2.20) with no difference between the two groups (RM-ON vs. RM-OFF weighted-HR, 0.88; CI, 0.36–2.13; p=.78). In the RM-ON group, 100% AHREs evaluated within 11days from onset, and within 202days in the RM-OFF group, with a median evaluation delay 79days shorter in the RM-ON group versus the RM-OFF group (p&nbsp

Published
2022
Full Text
View/download PDF

35. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review

Author

Mohammad Said Ramadan, Lorenzo Bertolino, Rosa Zampino, Emanuele Durante-Mangoni, Domenico Iossa, Maria Paola Ursi, Fabiana D'Amico, Arta Karruli, Mohammad Ramadan, Roberto Andini, Mariano Bernardo, Giuseppe Ruocco, Giovanni Dialetto, Franco Enrico Covino, Sabrina Manduca, Alessandro Della Corte, Marisa De Feo, Stefano De Vivo, Maria Luisa De Rimini, Nicola Galdieri, Ramadan, M. S., Bertolino, L., Zampino, R., Durante-Mangoni, E., Iossa, D., Ursi, M. P., D'Amico, F., Karruli, A., Ramadan, M., Andini, R., Bernardo, M., Ruocco, G., Dialetto, G., Covino, F. E., Manduca, S., Della Corte, A., De Feo, M., De Vivo, S., De Rimini, M. L., and Galdieri, N.

Subjects
0301 basic medicine, Microbiology (medical), Adult, medicine.medical_specialty, Heart Injury, Heart Diseases, Coronaviru, 030106 microbiology, Diastole, Magnetic Resonance Imaging, Cine, Cardiac effects post COVID-19, 03 medical and health sciences, Electrocardiography, 0302 clinical medicine, Cardiac magnetic resonance imaging, Internal medicine, Post-acute COVID-19, medicine, Humans, 030212 general & internal medicine, CMR, Prospective cohort study, Subclinical infection, Long COVID-19, medicine.diagnostic_test, business.industry, SARS-CoV-2, COVID-19, Retrospective cohort study, General Medicine, Cardiac sequelae, Heart Disease, Infectious Diseases, Echocardiography, COVID-19 Nucleic Acid Testing, Cohort, Heart injury, Systematic Review, business, Human
Abstract

Background: Coronavirus disease 2019 (COVID-19) has been implicated in a wide spectrum of cardiac manifestations following the acute phase of the disease. Objectives: To assess the range of cardiac sequelae after COVID-19 recovery. Data sources: PubMed, Embase, Scopus (inception through 17 February 2021) and Google scholar (2019 through 17 February 2021). Study eligibility criteria: Prospective and retrospective studies, case reports and case series. Participants: Adult patients assessed for cardiac manifestations after COVID-19 recovery. Exposure: Severe acute respiratory syndrome coronavirus 2 infection diagnosed by PCR. Methods: Systematic review. Results: Thirty-five studies (fifteen prospective cohort, seven case reports, five cross-sectional, four case series, three retrospective cohort and one ambidirectional cohort) evaluating cardiac sequelae in 52 609 patients were included. Twenty-nine studies used objective cardiac assessments, mostly cardiac magnetic resonance imaging (CMR) in 16 studies, echocardiography in 15, electrocardiography (ECG) in 16 and cardiac biomarkers in 18. Most studies had a fair risk of bias. The median time from diagnosis/recovery to cardiac assessment was 48 days (1–180 days). Common short-term cardiac abnormalities (

Published
2021

36. Sentinel lymph node biopsy versus PET-CT in AJCC stages I and II of melanoma

Author

Marco Adriano Chessa, Stefania Diodato, Pier Alessandro Fanti, Stefano Fanti, S. De Vivo, Emi Dika, Annalisa Patrizi, Giulia Veronesi, Bianca Maria Piraccini, Chessa, M A, Dika, E, Patrizi, A, Fanti, P A, Piraccini, B M, Veronesi, G, Diodato, S, De Vivo, S, and Fanti, S

Subjects
medicine.medical_specialty, PET-CT, medicine.diagnostic_test, business.industry, Melanoma, Sentinel lymph node, Dermatology, medicine.disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, 030220 oncology & carcinogenesis, Biopsy, medicine, Neoplasm staging, Radiology, business, Positron Emission Tomography-Computed Tomography, Bima-2017
Published
2017

37. Collagen-Based Vascular Closure Device Multicenter Italian Experience in Endovascular Aortic Aneurysm Repair Compared With Suture-Mediated Closure Vascular Device.

Author

Panagrosso M, Cavallo E, Bracale UM, Peluso A, Silvestri O, Intrieri F, Molinari V, Esposito A, Trimarchi S, Settembrini AM, Lomazzi C, La Barbera G, Carbonari L, Angelini A, Morelli I, Centonza E, Berchiolli R, Troisi N, Scarati V, Artini V, De Vivo S, Volpe P, Massara M, and Martelli E

Abstract

Purpose: The Manta Vascular Closure Device is a novel collagen-based vascular closure device that has been designed specifically for closure of large-bore percutaneous arterial accesses. The aim of this retrospective study is to evaluate the immediate and 30-day outcome of Manta at the completion of endovascular aneurysm repair (EVAR) or thoracic endovascular aortic repair (TEVAR). The hypothesis is that Manta is not inferior in obtaining hemostasis compared with the Perclose ProGlide Suture-Mediated Closure System device., Materials and Methods: We recruited all the percutaneous accesses for (T)EVAR performed from January 2021 to April 2023 by all the Italian Divisions of Vascular Surgery using Manta at the time of data collection (May 2023). The primary outcome is to evaluate the incidence of complications at the puncture site after Manta implantation and at 1 month, and compare this with ProGlide. We applied the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) criteria for observational studies., Results: Overall, 524 consecutive femoral accesses for (T)EVAR procedures were collected: 355 in the Manta cohort and 169 in the ProGlide cohort, respectively. The size of the sheath was 17.2±2.7 Fr for Manta, 15.7±2.3 Fr for ProGlide (p<0.001). No statistically significant differences between the groups regarding age, sex, body mass index, ultrasound-guided access, femoral calcifications, intraoperative, and 30-day complications. Successful arterial closure at groin puncture sites for (T)EVAR using Manta is 90.5% and 93.1% using ProGlide. Freedom for any reintervention for any complication is 95.5% for Manta and 96% for ProGlide., Conclusion: The 2 vascular closure devices have proved to be similar in terms of complications, without any statistically significant difference, although the median size of the sheaths for (T)EVAR was statistically significantly larger when Manta has been used, compared with ProGlide., Clinical Impact: Manta® is effective in the hemostasis of the access sites following the completion of (T)EVAR in this multicenter, retrospective, case-control study on 524 percutaneous femoral accesses. Compared to the more popular Proglide®, the average size of the introducers in the Manta® group was significantly larger than in the Proglide® group., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Published
2024
Full Text
View/download PDF

38. Can we encourage the endoscopic treatment for external snapping hip (ESH)? A systematic review of current concepts.

Author

Giai Via R, Elzeiny A, Pantè S, De Vivo S, Massè A, and Giachino M

Subjects
Humans, Endoscopy methods, Joint Diseases surgery, Hip Joint surgery, Hip Joint physiopathology, Tenotomy methods, Arthroscopy methods
Abstract

Background: Snapping hip syndrome (SHS) is characterized by snapping sensation and pain and affects up to 10% of the general population. External snapping hip syndrome (ESHS), the most common form, is often due to repetitive movements in sports or anatomical predispositions. Conservative treatment includes physiotherapy and corticosteroid injections, while surgery is considered if conservative measures fail. Open surgical techniques carry several risks, while modern arthroscopic techniques offer less invasive options, such as endoscopic iliotibial band release (ITB) and gluteus maximus tenotomy., Materials and Methods: A systematic review was conducted adhering to the PRISMA guidelines. Relevant studies were searched in four databases: Pubmed, Scopus, Embase, and Medline. The selected articles were evaluated according to the criteria of levels of evidence. The Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) was used to analyze the retrospective studies. This paper was registered in the International Prospective Registry of Systematic Reviews (PROSPERO)., Results: Out of 9 included studies, 403 patients with 689 hips underwent endoscopic treatment. ITB release and his variations were the main surgical techniques. Gluteus maximus tenotomy was also used in some studies. Postoperative rehabilitation protocols varied. Patients generally experienced significant improvements in symptoms and functional outcomes, with low rates of recurrence (1.02%) and revision (0.15%). Complications were minimal., Conclusions: Endoscopic treatment of ESH shows favorable results, improving functional outcomes and returning patients to pre-injury activity levels. Long-term efficacy and costeffectiveness need to be evaluated, emphasizing the importance of large-scale prospective randomized trials to clarify surgery's benefits in refractory ESH cases., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

39. Arthroscopic and endoscopic techniques for iliopsoas release in THA are safe and effective: a systematic review of the literature.

Author

Giai Via R, Giachino M, Elzeiny A, Donis A, De Vivo S, Bosco F, and Massè A

Subjects
Humans, Psoas Muscles surgery, Endoscopy methods, Endoscopy adverse effects, Tenotomy methods, Tenotomy adverse effects, Treatment Outcome, Postoperative Complications etiology, Reoperation statistics & numerical data, Pain, Postoperative etiology, Arthroscopy methods, Arthroscopy adverse effects, Arthroplasty, Replacement, Hip methods, Arthroplasty, Replacement, Hip adverse effects
Abstract

Background: Hip replacement surgery is highly effective in relieving pain and improving mobility in patients with various hip conditions. However, some patients develop groin pain after surgery, often due to iliopsoas impingement (IPI), which can be challenging to diagnose. Conservative treatments are initially recommended, but when these are not effective, surgical options may be considered. This study aims to evaluate the clinical outcomes, success and failure rates, revision rates, and complications associated with arthroscopic and endoscopic surgery for IPI, thereby providing a comprehensive understanding of the effectiveness and risks of these surgical interventions., Materials and Methods: A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including a thorough search of five main databases: PubMed, Scopus, Embase, Medline, and Cochrane. Eligible articles were meticulously evaluated according to predefined criteria for levels of evidence (LoE), with retrospective studies assessed using the Coleman Methodology Score (mCMS). This systematic review was registered in the International Prospective Registry of Systematic Reviews (PROSPERO)., Results: Among the 16 included studies, 431 patients with 434 hips underwent either endoscopic or arthroscopic tenotomy. Both techniques showed favorable outcomes, with arthroscopic tenotomy demonstrating slightly higher success rates than endoscopic tenotomy. Common complications included mild pain and occasional infections, with recurrence observed in some cases. Both techniques offer direct visualization of prosthetic components and potential preservation of psoas function., Conclusions: Arthroscopic and endoscopic iliopsoas tenotomy are effective treatments for alleviating symptoms and improving hip function in patients with IPI post-total hip arthroplasty (THA)., Level of Evidence: IV., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

40. Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study.

Author

Macaluso FS, D'Antonio E, Fries W, Viola A, Ksissa O, Cappello M, Muscarella S, Belluardo N, Giangreco E, Mocciaro F, Di Mitri R, Ferracane C, Vitello A, Grova M, Renna S, Casà A, De Vivo S, Ventimiglia M, and Orlando A

Subjects
Humans, Piperidines adverse effects, Colitis, Ulcerative drug therapy, Inflammatory Bowel Diseases drug therapy
Abstract

Background: Real-world evidence is needed to determine the value of tofacitinib (TOFA) for the treatment of ulcerative colitis (UC)., Aim: To assess the safety and effectiveness of TOFA in clinical practice., Methods: TOFA-UC is a multicenter, observational study performed among the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). All consecutive patients with UC starting TOFA from its introduction in Sicily (July 2021) to July 2022 were included., Results: 111 patients were included (mean follow-up: 31.7 ± 14.9 weeks; biologic-experienced: 92.8%). Nineteen adverse events were reported (17.1%; incidence rate: 28.2 per 100 patient years), including 11 cases of hypercholesterolemia and 3 infections (no cases of herpes zoster reactivation. At week 8, the rates of clinical response, steroid free clinical remission, and CRP normalization were 74.8%, 45.0%, and 56.9%, respectively, and 68.5%, 51.4%, and 65.2%, respectively, at the end of follow-up. Eighteen patients experienced a loss of response after successful induction (21.7%; incidence rate: 33.2 per 100 patient years). Twenty-six patients (23.4%) discontinued TOFA over time, of whom 3 due to AEs, and 23 to non response or loss of response., Conclusions: TOFA is safe and effective in patients with UC, including those with history of multiple failures to biological therapies., Competing Interests: Conflict of interest Fabio Salvatore Macaluso served as an advisory board member and/or received lecture grants from Biogen, Ferring, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals. Walter Fries served as an advisory board member and/or received lecture grants from Abbvie, MSD, Takeda, Pfizer, Biogen, Sandoz, Zambon, Ferring Italia, Sofar. Anna Viola received lecture grants from Pfizer. Maria Cappello served as an advisory board member for AbbVie, MSD, Takeda Pharmaceuticals, and received lecture grants from AbbVie, MSD, Chiesi, and Takeda Pharmaceuticals. Filippo Mocciaro served as an advisory board member for Janssen and Galapagos, and received lecture grants from Takeda Pharmaceuticals. Antonino Carlo Privitera served as consultant to Mundipharma, Abbvie, MSD, Takeda, and Janssen, and received lecture fees from Abbvie, Sara Renna served as an advisory board member for AbbVie, Janssen, and MSD Pharmaceuticals, and received lecture grants from AbbVie, Janssen, MSD, Pfizer, and Takeda Pharmaceuticals. Ambrogio Orlando served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals, and received lecture grants from AbbVie, Fresenius Kabi, Galapagos, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals., (Copyright © 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)

Published
2024
Full Text
View/download PDF

41. New Psychometric Strategies for the Evaluation of Affective, Cognitive, and Psychosocial Functioning in Unipolar versus Bipolar Depression: Impact of Drug Treatment.

Author

Guerrera CS, Platania GA, Varrasi S, De Vivo S, Pirrone C, Vezzosi VF, Tascedda F, Drago F, Di Nuovo S, Blom JMC, Castellano S, and Caraci F

Abstract

Background: Different studies have been conducted to understand how patients with unipolar and bipolar depression differ in terms of cognitive and affective symptoms as well as in psychosocial function. Furthermore, the impact of antidepressants, second-generation antipsychotics, and mood stabilizers on these dimensions needs to be characterized, as well as the best psychometric approach to measure changes after pharmacological treatment., Objectives: This study aims to analyze the impact of psychotropic drugs on cognitive, affective, and psychosocial functioning in MDD and BD patients; to test the sensitivity of psychometric tools for measuring those changes; also, to understand how psychosocial abilities are associated with affective and cognitive dimensions in patients with MDD and BD., Methods: A total of 22 patients with MDD and 21 patients with BD in the depressive phase were recruited. Several psychometric tests were administered to assess affective, cognitive, and psychosocial symptoms before and after 12 weeks of drug treatment (T0 and T1) with different psychotropic drugs including second-generation antidepressants, second-generation antipsychotics and mood stabilizers (lamotrigine)., Results: MDD patients showed significant improvement in MoCA, Delayed Recall of Rey's 15 Words and HDRS, while a significant worsening was detected on Digit Span Backwards and on FAST scores. Instead, patients with BD showed significant improvements in the MoCA as the MDD patients, but only a trend of improvement (non-statistically significant) on the BDI-II. A positive correlation was detected in both groups between FAST and HDRS and BDI-II scores, especially in BD patients., Conclusion: Our results demonstrate that drug treatment with psychotropic drugs can improve cognitive and affective symptoms, but not all psychometric tools may be equally sensitive to detect those changes in MDD vs. BD patients. Moreover, we found that affective and cognitive dimensions can be considered as different psychopathological dimensions both in unipolar and bipolar depression., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Published
2024
Full Text
View/download PDF

42. Leadless Pacemaker Infection Risk in Patients with Cardiac Implantable Electronic Device Infections: A Case Series and Literature Review.

Author

Bertolino L, Florio LL, Patauner F, Gallo R, Peluso AM, Scafuri A, De Vivo S, Corrado C, Zampino R, Ruocco G, D'Onofrio A, and Durante-Mangoni E

Abstract

(1) Background: Leadless pacemakers (LPs) have been proposed as a reimplantation strategy in pacing-dependent patients undergoing cardiac implantable electronic device (CIED) extraction for infection. In this study, we analysed the risk of LP infection when this device is implanted before lead extraction. (2) Methods: This was a retrospective study including patients who underwent LP implantation between 2017 and 2022. Patients were divided in two groups according to whether LP was implanted following CIED extraction for infection (Group 1) or other indications (Group 2). The primary aim was to describe the risk of LP infection. (3) Results: We included in this study 49 patients with a median age of 81 [20-94] years, mostly males (36, 73%). In Group 1 patients, 17 cases (85%) showed systemic CIED infections, and 11 (55%) had positive lead cultures. Most Group 1 cases (n = 14, 70%) underwent one stage of LP implantation and CIED extraction. Mortality rate during follow-up was 20% (nine patients). Patients were followed up for a median of 927 [41-1925], days and no cases of definite or suspected LP infections were identified. (4) Conclusions: The risk of LP infection was extremely low. LP appears as a potential option for reimplantation in this setting and should be considered in pacing-dependent patients at a high risk of CIED infection recurrence.

Published
2023
Full Text
View/download PDF

43. The dynamic interaction between symptoms and pharmacological treatment in patients with major depressive disorder: the role of network intervention analysis.

Author

Guerrera CS, Platania GA, Boccaccio FM, Sarti P, Varrasi S, Colliva C, Grasso M, De Vivo S, Cavallaro D, Tascedda F, Pirrone C, Drago F, Di Nuovo S, Blom JMC, Caraci F, and Castellano S

Subjects
Humans, Antidepressive Agents, Selective Serotonin Reuptake Inhibitors therapeutic use, Depressive Disorder, Major drug therapy, Depressive Disorder, Treatment-Resistant drug therapy
Abstract

Introduction: The Major Depressive Disorder (MDD) is a mental health disorder that affects millions of people worldwide. It is characterized by persistent feelings of sadness, hopelessness, and a loss of interest in activities that were once enjoyable. MDD is a major public health concern and is the leading cause of disability, morbidity, institutionalization, and excess mortality, conferring high suicide risk. Pharmacological treatment with Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) is often the first choice for their efficacy and tolerability profile. However, a significant percentage of depressive individuals do not achieve remission even after an adequate trial of pharmacotherapy, a condition known as treatment-resistant depression (TRD)., Methods: To better understand the complexity of clinical phenotypes in MDD we propose Network Intervention Analysis (NIA) that can help health psychology in the detection of risky behaviors, in the primary and/or secondary prevention, as well as to monitor the treatment and verify its effectiveness. The paper aims to identify the interaction and changes in network nodes and connections of 14 continuous variables with nodes identified as "Treatment" in a cohort of MDD patients recruited for their recent history of partial response to antidepressant drugs. The study analyzed the network of MDD patients at baseline and after 12 weeks of drug treatment., Results: At baseline, the network showed separate dimensions for cognitive and psychosocial-affective symptoms, with cognitive symptoms strongly affecting psychosocial functioning. The MoCA tool was identified as a potential psychometric tool for evaluating cognitive deficits and monitoring treatment response. After drug treatment, the network showed less interconnection between nodes, indicating greater stability, with antidepressants taking a central role in driving the network. Affective symptoms improved at follow-up, with the highest predictability for HDRS and BDI-II nodes being connected to the Antidepressants node., Conclusion: NIA allows us to understand not only what symptoms enhance after pharmacological treatment, but especially the role it plays within the network and with which nodes it has stronger connections., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

44. Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.

Author

Macaluso FS, Grova M, Mocciaro F, Di Mitri R, Privitera AC, Distefano ME, Vitello A, Camilleri S, Ferracane C, Pluchino D, Belluardo N, Giangreco E, Fries W, Viola A, Cappello M, D'Amato L, Bertolami C, Ventimiglia M, Renna S, Casà A, D'Antonio E, De Vivo S, and Orlando A

Subjects
Humans, Ustekinumab therapeutic use, Colon surgery, Neoplasm Recurrence, Local, Colonoscopy, Recurrence, Retrospective Studies, Crohn Disease drug therapy, Crohn Disease surgery
Abstract

Background and Aim: Postoperative recurrence (POR) following ileocolonic resection is a major concern in patients with Crohn's disease (CD). The role of ustekinumab (UST) in this setting is poorly known., Methods: All consecutive CD patients with a baseline colonoscopy at 6-12 months from ileocolonic resection showing POR (Rutgeerts score ≥ i2) who were treated with UST after the baseline colonoscopy and with an available post-treatment endoscopy, were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). The primary outcome was endoscopic success, defined as reduction of at least one point of Rutgeerts score. The secondary outcome was clinical success, assessed at the end of follow-up. Reasons for clinical failure included mild clinical relapse (Harvey-Bradshaw index 5-7), clinically relevant relapse (Harvey-Bradshaw index > 7), and need for new resection., Results: Forty-four patients were included (mean follow-up: 17.8 ± 8.4 months). The baseline postoperative colonoscopy showed severe POR (Rutgeerts score i3 or i4) in 75.0% of patients. The post-treatment colonoscopy was performed after a mean of 14.5 ± 5.5 months following initiation of UST. Endoscopic success was reported in 22 out of 44 (50.0%) patients, of whom 12 (27.3%) achieved a Rutgeerts score i0 or i1. Clinical success at the end of follow-up was reported in 32 out of 44 patients (72.7%); none of the 12 patients with clinical failure had achieved endoscopic success at post-treatment colonoscopy., Conclusions: Ustekinumab could be a promising option for the treatment of POR of CD., (© 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)

Published
2023
Full Text
View/download PDF

45. Safety and Efficacy of a Single Procedure of Extraction and Reimplantation of Infected Cardiovascular Implantable Electronic Device (CIED) in Comparison with Deferral Timing: An Observational Retrospective Multicentric Study.

Author

Tascini C, Giuliano S, Attanasio V, Segreti L, Ripoli A, Sbrana F, Severino S, Sordelli C, Weisz SH, Zanus-Fortes A, Leanza GM, Carannante N, Di Cori A, Bongiorni MG, Zucchelli G, and De Vivo S

Abstract

(1) Background: Infections are among the most frequent and life-threatening complications of cardiovascular implantable electronic device (CIED) implantation. The aim of this study is to compare the outcome and safety of a single-procedure device extraction and contralateral implantation versus the standard-of-care (SoC) two-stage replacement for infected CIEDs. (2) Methods: We retrospectively included 66 patients with CIED infections who were treated at two Italian hospitals. Of the 66 patients enrolled in the study, 27 underwent a single procedure, whereas 39 received SoC treatment. All patients were followed up for 12 months after the procedure. (3) Results: Considering those lost to follow-up, there were no differences in the mortality rates between the two cohorts, with survival rates of 81.5% in the single-procedure group and 84.6% in the SoC group ( p = 0.075). (4) Conclusions: Single-procedure reimplantation associated with an active antibiofilm therapy may be a feasible and effective therapeutic option in CIED-dependent and frail patients. Further studies are warranted to define the best treatment regimen and strategies to select patients suitable for the single-procedure reimplantation.

Published
2023
Full Text
View/download PDF

47. Infective Endocarditis Associated with Implantable Cardiac Device by Metallo-β-Lactamase-Producing Pseudomonas aeruginosa, Successfully Treated with Source Control and Cefiderocol Plus Imipenem.

Author

Tascini C, Antonelli A, Pini M, De Vivo S, Aiezza N, Bernardo M, Di Luca M, and Rossolini GM

Subjects
Humans, Imipenem therapeutic use, Pseudomonas aeruginosa, Anti-Bacterial Agents therapeutic use, beta-Lactamases genetics, Microbial Sensitivity Tests, Cefiderocol, Defibrillators, Implantable, Endocarditis, Pseudomonas Infections drug therapy
Published
2023
Full Text
View/download PDF

48. Predictors of functional outcome in patients with major depression and bipolar disorder: A dynamic network approach to identify distinct patterns of interacting symptoms.

Author

Platania GA, Savia Guerrera C, Sarti P, Varrasi S, Pirrone C, Popovic D, Ventimiglia A, De Vivo S, Cantarella RA, Tascedda F, Drago F, Di Nuovo S, Colliva C, Caraci F, Castellano S, and Blom JMC

Subjects
Humans, Depression, Prospective Studies, Executive Function, Bipolar Disorder, Depressive Disorder, Major
Abstract

The purpose of this study is to use a dynamic network approach as an innovative way to identify distinct patterns of interacting symptoms in patients with Major Depressive Disorder (MDD) and patients with Bipolar Type I Disorder (BD). More precisely, the hypothesis will be testing that the phenotype of patients is driven by disease specific connectivity and interdependencies among various domains of functioning even in the presence of underlying common mechanisms. In a prospective observational cohort study, hundred-forty-three patients were recruited at the Psychiatric Clinic "Villa dei Gerani" (Catania, Italy), 87 patients with MDD and 56 with BD with a depressive episode. Two nested sub-groups were treated for a twelve-week period, which allowed us to explore differences in the pattern of symptom distribution (central vs. peripheral) and their connectedness (strong vs weak) before (T0) and after (T1) treatment. All patients underwent a complete neuropsychological evaluation at baseline (T0) and at T1. A network structure was computed for MDD and BD patients at T0 and T1 from a covariance matrix of 17 items belonging to three domains-neurocognitive, psychosocial, and mood-related (affective) to identify what symptoms were driving the networks. Clinically relevant differences were observed between MDD and BD, at T0 and after 12 weeks of pharmacological treatment. At time T0, MDD patients displayed an affective domain strongly connected with the nodes of psychosocial functioning, while direct connectivity of the affective domain with the neurocognitive cluster was absent. The network of patients with BD, in contrast, revealed a cluster of highly interconnected psychosocial nodes but was guided by neurocognitive functions. The nodes related to the affective domain in MDD are less connected and placed in the periphery of the networks, whereas in BD they are more connected with psychosocial and neurocognitive nodes. Noteworthy is that, from T0 to T1 the "Betweenness" centrality measure was lower in both disorders which means that fewer "shortest paths" between nodes pass through the affective domain. Moreover, fewer edges were connected directly with the nodes in this domain. In MDD patients, pharmacological treatment primarily affected executive functions which seem to improve with treatment. In contrast, in patients with BD, treatment resulted in improvement of overall connectivity and centrality of the affective domain, which seems then to affect and direct the overall network. Though different network structures were observed for MDD and BD patients, data suggest that treatment should include tailored cognitive therapy, because improvement in this central domain appeared to be fundamental for better outcomes in other domains. In sum, the advantage of network analysis is that it helps to predict the trajectory of future phenotype related disease manifestations. In turn, this allows new insights in how to balance therapeutic interventions, involving different fields of function and combining pharmacological and non-pharmacological treatment modalities., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Platania et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2023
Full Text
View/download PDF

49. Sex-Related Differences and Factors Associated with Peri-Procedural and 1 Year Mortality in Chronic Limb-Threatening Ischemia Patients from the CLIMATE Italian Registry.

Author

Martelli E, Zamboni M, Sotgiu G, Saderi L, Federici M, Sangiorgi GM, Puci MV, Martelli AR, Messina T, Frigatti P, Borrelli MP, Ruotolo C, Ficarelli I, Rubino P, Pezzo F, Carbonari L, Angelini A, Galeazzi E, Di Pinto LC, Fiore FM, Palmieri A, Ventoruzzo G, Mazzitelli G, Ragni F, Bozzani A, Forliti E, Castagno C, Volpe P, Massara M, Moniaci D, Pagliasso E, Peretti T, Ferrari M, Troisi N, Modugno P, Maiorano M, Bracale UM, Panagrosso M, Monaco M, Giordano G, Natalicchio G, Biello A, Celoria GM, Amico A, Di Bartolo M, Martelli M, Munaó R, Razzano D, Colacchio G, Bussetti F, Lanza G, Cardini A, Di Benedetto B, De Laurentis M, Taurino M, Sirignano P, Cappiello P, Esposito A, Trimarchi S, Romagnoli S, Padricelli A, Giudice G, Crinisio A, Di Nardo G, Battaglia G, Tringale R, De Vivo S, Compagna R, Tolva VS, D'Alessio I, Curci R, Giovannetti S, D'Arrigo G, Basile G, Frigerio D, Veraldi GF, Mezzetto L, Ippoliti A, Oddi FM, and Settembrini AM

Abstract

Background: Identifying sex-related differences/variables associated with 30 day/1 year mortality in patients with chronic limb-threatening ischemia (CLTI)., Methods: Multicenter/retrospective/observational study. A database was sent to all the Italian vascular surgeries to collect all the patients operated on for CLTI in 2019. Acute lower-limb ischemia and neuropathic-diabetic foot are not included., Follow-Up: One year. Data on demographics/comorbidities, treatments/outcomes, and 30 day/1 year mortality were investigated., Results: Information on 2399 cases (69.8% men) from 36/143 (25.2%) centers. Median (IQR) age: 73 (66-80) and 79 (71-85) years for men/women, respectively ( p < 0.0001). Women were more likely to be over 75 (63.2% vs. 40.1%, p = 0.0001). More men smokers (73.7% vs. 42.2%, p < 0.0001), are on hemodialysis (10.1% vs. 6.7%, p = 0.006), affected by diabetes (61.9% vs. 52.8%, p < 0.0001), dyslipidemia (69.3% vs. 61.3%, p < 0.0001), hypertension (91.8% vs. 88.5%, p = 0.011), coronaropathy (43.9% vs. 29.4%, p < 0.0001), bronchopneumopathy (37.1% vs. 25.6%, p < 0.0001), underwent more open/hybrid surgeries (37.9% vs. 28.8%, p < 0.0001), and minor amputations (22% vs. 13.7%, p < 0.0001). More women underwent endovascular revascularizations (61.6% vs. 55.2%, p = 0.004), major amputations (9.6% vs. 6.9%, p = 0.024), and obtained limb-salvage if with limited gangrene (50.8% vs. 44.9%, p = 0.017). Age > 75 (HR = 3.63, p = 0.003) is associated with 30 day mortality. Age > 75 (HR = 2.14, p < 0.0001), nephropathy (HR = 1.54, p < 0.0001), coronaropathy (HR = 1.26, p = 0.036), and infection/necrosis of the foot (dry, HR = 1.42, p = 0.040; wet, HR = 2.04, p < 0.0001) are associated with 1 year mortality. No sex-linked difference in mortality statistics., Conclusion: Women exhibit fewer comorbidities but are struck by CLTI when over 75, a factor associated with short- and mid-term mortality, explaining why mortality does not statistically differ between the sexes.

Published
2023
Full Text
View/download PDF

50. Effects of Cardiac Contractility Modulation Electrodes on Tricuspid Regurgitation in Patients with Heart Failure with Reduced Ejection Fraction: A Pilot Study.

Author

Masarone D, Kittleson MM, De Vivo S, D'Onofrio A, Rao I, Ammendola E, Errigo V, Martucci ML, Nigro G, and Pacileo G

Abstract

Background: Cardiac contractility modulation (CCM) is an innovative therapy for heart failure with reduced ejection fraction delivered by a cardiac implantable device (Optimizer Smart ® ). One of the most prominent periprocedural complications common to all cardiac implantable devices (CIDs) is tricuspid regurgitation (TR) due to the placement of the right ventricular endocardial leads. To date, no published studies have assessed the changes in the TR degree in patients with heart failure with reduced ejection fraction (HFrEF) who received an implantable cardioverter-defibrillator (ICD) after the implantation of cardiac contractility modulation therapy devices., Objective: This study aimed to evaluate the effect of the implantation of the trans-tricuspid leads required to deliver CCM therapy on the severity of TR in patients with HFrEF who previously underwent ICD implantation., Methods: We enrolled 30 HFrEF patients who underwent CCM therapy between November 2020 and October 2021. For all the patients, echocardiographic evaluations of TR were performed according to current guidelines 24 h before and six months after the Optimizer Smart ® implant was applied., Results: At the 6-month follow-up, the grade of TR remained unchanged compared to the preimplant grade. The value of the vena contracta (VC) of TR was 0.40 ± 0.19 cm in the preimplant period and 0.45 ± 0.21 cm at the 6-month follow-up ( p = 0.33). Similarly, the TR proximal isovelocity surface area (PISA) radius value was unchanged at follow-up (0.54 ± 0.22 cm vs. 0.62 ± 0.20 cm; p = 0.18). No statistically significant difference existed between the preimplant VC and PISA radius values, irrespective of the device type., Conclusions: The implantation of right ventricular electrodes for the delivery of CCM therapy did not worsen tricuspid regurgitation in patients with HFrEF and ICD.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results